RxDoctor Payments Data

Kenneth Arsham, MD

Plastic Surgery · Warrensville Heights, OHNPI 1841222411

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $9,456 of the $11,791 with a category attached, or 80.2%. Smith+Nephew accounts for 93.5% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $7,911 and has fallen 98.1% since, to $147 in 2025.

$11,791in general payments, 2019–2025

Across 49 payments — averaging $240.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$11K
  • KCI USA, Inc.$170
  • Galderma Laboratories, L.p.$146
  • Kerecis Limited$142
  • Musculoskeletal Transplant Foundation Inc.$131
  • Urgo Medical North America, LLC$130
  • plus $45 from 3 others

What the payments were for

  • Speaking & faculty fees$9,45680%
  • Travel & lodging$6946%
  • Food & beverage$1,64114%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,791 in reported general payments places this provider in the 85th percentile of 191 plastic surgery providers in Ohio.

See all plastic surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$447,494
Medicare patients
180
Services billed
1,624

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.15$17,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$11,027$17,16715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 191 plastic surgery providers in Ohio.

Other plastic surgery in Warrensville Heights

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →